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ABSTRACT
The involvement of estrogen (E2) and hypoxia in tumor progression is well 
established. Hypoxia has been reported to activate and degrade estrogen receptor 
alpha (ER`) in breast cancer cells. Furthermore, E2 has been shown to regulate 
hypoxia-inducible factor (HIF)-1` protein, but its role in HIF-2` regulation remains 
largely unexplored. In this study, we found that both HIF-2` mRNA and protein 
were down-regulated in ER positive but not ER negative breast cancer cells upon 
treatment with E2. The analysis of 690 samples derived from 608 mixed and 82 triple-
negative breast cancer patients revealed that high nuclear HIF-2` tumor levels are 
associated with a worse prognosis specifically in human epidermal growth factor 
receptor 2 (HER2) and hormone receptor positive patients. Consistently, ER`/HER2 
positive breast cancer cells displayed less pronounced downregulation of HIF-2` by 
E2. Experiments using a histone deacetylase inhibitor indicate that the E2 mediated 
decrease in HIF-2` mRNA is due to transcriptional repression. A functional estrogen 
response element (ERE) was identified in the first intron of the gene encoding HIF-
2` (EPAS1), suggesting transcriptional co-repressor recruitment by ER`. Our results 
demonstrate a novel modulation of HIF-2` in breast cancer cells, explaining the 
opposing regulation between HIF-1` and HIF-2` in hormone-responsive breast cancer.
INTRODUCTION
The ability of cancer cells to adapt to micro-
environmental tissue hypoxia is mainly mediated by 
hypoxia-inducible factors (HIFs), which affect every 
aspect of cancer progression, comprising metabolism, 
proliferation, inflammation, angiogenesis, metastasis 
and therapy resistance [1-4]. Transcriptionally active 
HIFs are heterodimers composed of a constitutively 
expressed β subunit and an oxygen labile HIF-1α or 
HIF-2α subunit, the stability and activity of which is 
regulated by prolyl-4-hydroxylase domain (PHD) and 
factor inhibiting HIF (FIH) enzymes [5]. Despite showing 
similar protein structures and having identical DNA 
recognition sequences, distinct - sometimes even opposite 
- functional roles of HIF-1α and HIF-2α in tumorigenesis 
have been reported [6-9]. We and others found different 
kinetics of hypoxic HIF-1α and HIF-2α protein induction 
and target gene expression [10, 11], further suggesting 
non-overlapping roles for these two related transcription 
factors.
Estrogens are steroid hormones and represent 
the primary female sex hormones, regulating diverse 
physiological processes in reproductive, mammary, 
cardiovascular, osseous, hepatic, and neuronal tissues 
[12-16]. The cellular effects of estrogens are mediated 
by two estrogen receptor (ER) isoforms, ERα and ERβ, 
which belong to the family of nuclear hormone receptors 
[17]. Ligand binding leads to the dissociation of heat 
shock proteins from the ER, which is followed by receptor 
dimerization and nuclear translocation. In the nucleus, 
the activated dimer complex binds to estrogen response 
elements (EREs) located within the regulatory regions of 
target genes [18].
Besides regulating numerous aspects of 
human physiology, estrogens also influence diverse 
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pathophysiological processes, including the onset 
and progression of breast cancer [19]. Breast cancer 
is the most common cancer in women worldwide and 
the second most common cancer overall. Approx. 1.7 
million new cases were diagnosed in 2012, which 
represents 12% and 25% of all new cancer cases and all 
cancers in women, respectively [20, 21]. The presence 
of elevated ERα levels in benign breast epithelium 
correlates with an increased risk of breast cancer, 
suggesting a role for ERα in breast cancer initiation [22]. 
17β-estradiol (E2), the dominant circulating estrogen, 
regulates the growth of many breast tumors, and approx. 
70% of breast cancers express ERα. Most of these ERα 
positive tumors depend on estrogen signaling for their 
growth and survival [23].
In conjunction with estrogen, hypoxia has been 
reported to play an important role in the development 
and progression of breast cancer [24-28]. In breast 
cancer cells, estrogen and hypoxia modulate the 
expression of genes involved in proliferation, 
differentiation, angiogenesis, metabolism and apoptosis 
[29-31]. Further studies revealed the presence of a 
cross-talk between estrogen signaling pathways and 
HIF-1α regulation in breast cancer [28, 32]. Estrogen 
has been reported to rapidly induce ERα-c-Src-PI3K 
interactions, which activates the PI3K/AKT/mTOR 
pathway and subsequent HIF-1α protein translation 
by phosphorylation of the p70 S6 kinase and 4EB-P1 
[27]. Activation of G protein-coupled receptor GPR30 
(GPER) by E2 triggers the GPER/EGFR/ERK/c-fos 
signaling pathway, leading to increased VEGF via 
HIF-1α upregulation [33]. Furthermore, ERα has been 
reported to directly induce HIF-1α transcription, which 
might modulate the anti-estrogen response in breast 
cancer treatment [32]. In contrast, ERβ has been reported 
to play an opposing role to ERα. Transcriptional activity 
of HIF-1 is inhibited by ERβ, which is mediated by 
ubiquitin-dependent degradation of HIF-β [27].
Despite the numerous studies on HIF-1α regulation 
by estrogen, the interaction between estrogen signaling 
and HIF-2α regulation is currently unknown. By 
immunohistochemical detection of HIF-2α in tissue 
microarrays of 282 invasive breast cancer cases we 
previously found that patients expressing high HIF-
2α levels had a better overall survival rate compared to 
patients expressing low nuclear HIF-2α [11]. Our study 
was confirmed by the designation of HIF-2α in a list of 
genes associated with favorable outcome based on studies 
with different cohorts of breast cancer patients [34]. 
Here, we report a previously not recognized regulation 
of HIF-2α by estrogen, suggesting an inverse interplay 
between estrogen and HIF-2α signaling, which might be 
involved in breast cancer progression. These data provide 
a more complex picture of the role of HIF-2α in breast 
cancer, including receptor status and hormone dependent 
regulation.
RESULTS
E2 downregulates HIF-2α mRNA and protein 
levels in ERα positive but not ERα negative 
breast cancer cell lines
We previously reported a HIF-2 specific regulation 
of WISP-2 expression in breast cancer cells [35]. Because 
WISP-2 is a known ERα target gene [36], we aimed 
for the analysis of the cooperation between estrogen 
and oxygen signaling. Therefore, the time-dependent 
effect of E2 treatment on HIF signaling in MCF-7 cells 
was investigated. Unexpectedly, HIF-2α mRNA levels 
were progressively reduced with increasing time of E2 
treatment (Figure 1A). Maximal inhibitory effects were 
reached after 12 to 24 hours, and the latter time-point was 
selected for all subsequent experiments, also based on our 
previous observation that HIF-2α protein levels in MCF-7 
cells are expressed maximally after 24 hours of hypoxic 
exposure [11].
We further tested the effects of E2 on HIF-2α in 
additional breast cancer cell lines, including another 
luminal-like ERα positive (T-47D), a basal B-like ERα 
negative (MDA-MB-231), and a basal A-like ERα 
negative (MDA-MB-468) cell line. Both, HIF-2α mRNA 
(Figure 1B) and hypoxically stabilized protein (Figure 
1C) levels were downregulated in the ERα positive MCF-
7 and T-47D but not in the ERα negative MDA-MB-231 
and MDA-MB-468 cell lines. Exposure to hypoxia (0.2% 
O2) for 24 hours generally did not affect the HIF-2α 
mRNA levels, except in MDA-MB-231 cells where HIF-
2α mRNA was induced. However, E2 did not alter this 
cell type-specific HIF-2α mRNA regulation. Neither HIF-
1α mRNA (Figure 1B) nor hypoxically stabilized HIF-1α 
protein levels (Figure 1C) were significantly affected by 
24 hours E2 treatment. These data suggest that HIF-2α 
is specifically downregulated by E2-ERα signaling on the 
mRNA level, which resulted in corresponding changes on 
the protein levels.
The selective estrogen receptor modulator 
tamoxifen prevents ERα-dependent HIF-2α 
downregulation
To further investigate the involvement of estrogen 
signaling in HIF-2α and HIF-1α regulation, MCF-7 cells 
were treated for 24 hours with the ERα-specific agonist 
propyl pyrazole triol (PPT) and with a selective agonist 
for GPR30 (G-1) under normoxic or hypoxic conditions. 
HIF-2α but not HIF-1α mRNA levels were downregulated 
by PPT but not by G-1 (Figure 2A). Progesterone receptor 
(PgR) was included as a positive control for ERα activation 
by PPT. Hypoxia inhibited PgR induction in MCF-7 
cells, probably due to the known hypoxic degradation 
of ERα protein in these cells [37], as also shown below 
in Figure 2E. Downregulation of HIF-2α mRNA by PPT 
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was confirmed in T-47D cells (Figure 2B). Similar data 
were obtained in MCF-7 cells on the protein level (Figure 
2C), suggesting the involvement of ERα but not GPR30 in 
estrogen-mediated HIF-2α inhibition.
The current first line therapy of ER positive breast 
cancer patients is the treatment with the selective estrogen 
receptor modulator (SERM) tamoxifen. Therefore, MCF-
7 cells were treated with E2, with or without tamoxifen, 
under normoxic or hypoxic conditions. As shown in Figure 
2D, tamoxifen at least partially prevented HIF-2α mRNA 
downregulation by E2, while HIF-1α mRNA levels were 
neither affected by E2 nor tamoxifen. Vice versa, PgR mRNA 
upregulation by E2 was partially prevented by tamoxifen. 
Corroborating the findings on the mRNA levels, tamoxifen 
also partially prevented the E2-mediated downregulation of 
the hypoxically stabilized HIF-2α protein levels (Figure 2E). 
The slight HIF-2α but not HIF-1α protein downregulation 
by tamoxifen may be explained by the similarly decreased 
mRNA levels. However, these findings suggest that SERMs 
can reverse the inhibitory effects of estrogen on HIF-2α.
Inverse correlation between HIF-2α and ERα 
mRNA levels in breast cancer
To complement the pharmacological E2 receptor 
modulation shown above, ERα was downregulated by 
Figure 1: HIF-2α regulation by estrogen in breast cancer cell lines. A. MCF-7 cells were treated with 10 nM E2 for the indicated 
time periods. HIF-2α mRNA levels were quantified by RT-qPCR, corrected for the endogenous L28 mRNA levels and normalized to the 
starting time point. B. ERα positive (MCF-7 and T-47D) and ERα negative (MDA-MB-231 and MDA-MB-468) breast cancer cell lines 
were treated with 10 nM E2 for 24 hours under normoxic or hypoxic conditions. HIF-2α mRNA levels were quantified as above. Shown 
are mean values ± standard errors of the mean (SEM) of three to four independent experiments. For statistical evaluation, the effects of 
E2 treatment were compared with the ethanol solvent control (Ctrl) treatment. *P<0.05; **P<0.01; ***P<0.001. C. HIF-2α protein was 
detected by immunoblotting and constitutively expressed β-actin was used as loading and blotting control.
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siRNA treatment of MCF-7 cells. Knockdown efficiency 
was confirmed by a 96% decrease of the constitutive 
ERα mRNA levels as well as by a 97% decrease of the 
E2-induced mRNA levels of the ERα target gene PgR 
(Figure 3A). Both, basal and E2-inhibited HIF-2α mRNA 
levels were significantly increased in siERα but not siCtrl 
treated MCF-7 cells. While E2 strongly downregulated 
HIF-2α mRNA levels in siCtrl cells, the remaining slight 
downregulation in siERα cells was not significant (Figure 
3A). Similar results were obtained in MCF-7 cells stably 
transfected with three independent shRNA constructs 
which resulted in 74-83% ERα knockdown efficiency and 
in a strong decrease of PgR, whereas constitutive HIF-
2α mRNA levels were enhanced (Figure 3B). Probably 
due to the remaining ERα, blockade of the E2-mediated 
HIF-2α downregulation and PgR upregulation was rather 
inefficient in shERα compared with siERα cells (data not 
shown). These findings were corroborated on the protein 
level where hypoxically stabilized HIF-2α but not HIF-1α 
is clearly less downregulated by E2 in siERα than in siCtrl 
treated MCF-7 cells (Figure 3C).
Figure 2: ERα-mediated regulation of HIF-2α by estrogen. MCF-7 (A and C) or T-47D (B) cells were treated for 24 hours with 
10 nM PPT, an ERα-specific agonist with approx. 400 times higher affinity towards ERα than towards ERβ, or 1 μM G1 (MCF-7 only), a 
GPER-specific agonist, under normoxic or hypoxic conditions. The mRNA (A and B) and protein (C) levels were determined by RT-qPCR 
and immunoblotting, respectively. D and E. Tamoxifen (5 μM) was added to MCF-7 cells with or without 10 nM E2 and mRNA (D) and 
protein (E) levels were determined. Shown are mean mRNA values ± SEM of three independent experiments. For statistical evaluation, the 
effects of E2 treatment were compared with DMSO solvent control (Ctrl) treatment. *P<0.05; ***P<0.001.
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Because the results shown above suggest an inverse 
correlation between HIF-2α and ERα mRNA levels in 
breast cancer cell lines, we explored transcriptome data 
from various clinical breast cancer studies employing 
the R2 microarray analysis and visualization platform 
(http://hgserver1.amc.nl/cgi-bin/r2/main.cgi). A study 
of 66 tamoxifen-treated breast cancer patients showed a 
significant negative correlation between the expression of 
HIF-2α and ERα (Figure 3D). Several additional datasets 
from three different microarray studies including 136, 116 
and 61 breast cancer patients, respectively, displayed a 
similar inverse correlation (Supplementary Figure 1).
High HIF-2α expression is a negative prognostic 
factor in HER2 positive breast cancer
To study the role of HIF-2α in breast tumorigenesis, 
two tissue microarrays containing invasive breast cancer 
tumor samples derived from 690 breast cancer patients 
with primary breast cancer were immunostained for HIF-
2α. The tissue microarrays contained areas from invasive 
breast cancer belonging to ERα positive, HER2 positive 
or triple-negative cases, as described previously [38]. 
The signals from the invasive breast cancer samples in 
the tissue microarrays were scored based on the presence 
Figure 3: Reciprocal regulation of HIF-2α and ERα. ERα was knocked down in MCF-7 cells using siERα (A and C) or shERα 
(B) and then treated with 10 nM E2 under normoxic or hypoxic conditions. mRNA and protein levels were subsequently determined by RT-
qPCR (A and B) and immunoblotting (C, upper panel), respectively. Shown are mean mRNA (A and B) and protein (C, lower panel) values 
± SEM of three independent experiments. For statistical evaluation, the effects of ERα silencing were compared with siCtrl cells; the effects 
of E2 treatment were compared with ethanol solvent control (Ctrl) treatment. n.s., not significant; *P<0.05; **P<0.01. D. Microarray data 
from public databases were compiled using the R2 genomic analysis tool. Significance of the negative correlation between HIF-2α (red 
dots) and ERα (blue squares) mRNA levels was assessed by one-way ANOVA.
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or absence of cytoplasmic and nuclear HIF-2α staining 
as exemplified in Figure 4A. When all 690 cancer cases 
were included, neither cytoplasmic nor nuclear HIF-2α 
correlated with overall survival (Figure 4B). Stratification 
of cytoplasmic and nuclear HIF-2α to nodal status, tumor 
stage and histological grade showed no correlation with 
overall survival (Supplementary Figure 2A-2F). Also the 
analysis of the 82 triple-negative breast tumor samples 
did not reveal any significant association between HIF-
2α levels and overall survival (Supplementary Figure 2G). 
However, stratification of nuclear HIF-2α according to the 
HER2 positivity status in 38 hormone receptor positive 
breast cancer patients displayed a significant negative 
correlation with overall survival in patients with high 
nuclear HIF-2α (Figure 4C).
Because the ERα positive breast cancer cell lines 
used in Figure 1 are not overexpressing HER2, we 
analyzed the hormone receptor and HER2 positive breast 
cancer cell line BT-474. While treatment with 10 nM E2 
for 24 hours downregulated HIF-2α mRNA levels (Figure 
4D), the fold inhibition was less pronounced than in MCF-
7 and T-47D cells (Figure 1), and cannot be detected on 
the protein level (Figure 4E). Whereas strongly HER2 
overexpressing cell lines are quite rare, ZR-75-1 has been 
reported to be HER2 positive [39]. We hence repeated 
these experiments in ZR-75-1 cells which showed no HIF-
2α downregulation by E2, neither on the mRNA (Figure 
4F) nor on the protein (Figure 4G) level, confirming the 
results obtained in BT-474.
In conclusion, diminished downregulation of HIF-
2α by E2 in HER2 high ERα positive BT-474 and ZR-
75-1 cells is consistent with the correlation between high 
HIF-2α levels and worse survival of hormone receptor and 
HER2 positive breast cancer patients.
Figure 4: HIF-2α as a prognostic factor in HER2 positive breast cancer. A. Scoring system and representative images for 
cytoplasmic and nuclear HIF-2α staining of invasive breast cancer tissues. B. HIF-2α was scored in tissue microarrays of 608 invasive 
breast cancer cases (excluding triple-negative cases) and displayed in Kaplan-Meier survival curves. C. Survival curves of hormone 
receptor positive and HER2 overexpressing breast cancer patients according to HIF-2α scores. D to G. Triple-positive BT-474 and ZR-75-1 
breast cancer cells were treated with 10 nM E2 for 24 hours under normoxic or hypoxic conditions, and mRNA (D, F) and protein (E, G) 
levels of HIF-2α were determined. Shown are mean mRNA values ± SEM of three independent experiments. For statistical evaluation, the 
effects of E2 treatment were compared with ethanol solvent control (Ctrl) treatment. *P<0.05; n.s., not significant.
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ERα-dependent HIF-2α downregulation is 
independent of mutual HIFα inhibition or HIF-
2α mRNA stability
To address the functional mechanism underlying 
HIF-2α inhibition by E2/ERα, we investigated known 
candidate HIF-2α inhibitors. We and others previously 
reported the mutual inhibition of HIF-1α and HIF-2α 
[40, 7]. Because E2 has been shown to induce HIF-1α 
expression [33], we hypothesized that increased HIF-1α 
might subsequently decrease HIF-2α. This hypothesis 
was tested by adding E2 to stably HIF-1α or HIF-2α 
depleted MCF-7 cells. As expected, shHIF-1α MCF-7 
cells express higher levels of HIF-2α mRNA, whereas 
shHIF-2α had no effect on HIF-1α mRNA levels in this 
cell line (Figure 5A). Both, PgR and ERα remained largely 
unaffected by either HIF-1α or HIF-2α knockdown, and 
E2 downregulated HIF-2α in shHIF-1α to the same extent 
as in shCtrl cells. Also CITED-2, a preferential HIF-2 
target gene [41, 10], was still downregulated by E2 in 
shHIF-1α MCF-7 cells (Figure 5A). Similar results were 
obtained on the protein level (Figure 5B), suggesting that 
mutual HIFα inhibition does not play any role in E2/ERα-
dependent HIF-2α downregulation.
Because E2/ERα-mediated HIF-2α mRNA 
downregulation could be due to either transcriptional 
repression or decreased mRNA stability, we next analyzed 
the decrease of HIF-2α mRNA following RNA polymerase II 
inhibition by actinomycin D. As shown in Figure 5C, HIF-2α 
mRNA decay was not significantly different in the presence 
of E2 compared with solvent control, suggesting that HIF-2α 
mRNA levels were transcriptionally decreased by E2.
Histone deacetylation is involved in HIF-2α 
inhibition by E2
Histone deacetylation is one of the prerequisites for 
chromatin remodeling and regulation of gene expression. 
In order to study the role of histone deacetylation in 
HIF-2α transcriptional regulation, MCF-7 cells were 
treated with E2 in the absence or presence of the class I 
and II mammalian histone deacetylase (HDAC) inhibitor 
trichostatin A (TSA). While TSA alone had no effect, 
it prevented HIF-2α mRNA (Figure 6A) and protein 
Figure 5: Mutual HIF-α inhibition or mRNA stability are not involved in E2-dependent HIF-2α regulation. A. MCF-7 
shCtrl, shHIF-1α and shHIF-2α cells were treated with 10 nM E2 for 24 hours under hypoxic conditions and mRNA levels determined 
by RT-qPCR. Shown are mean values ± SEM of three independent experiments. The effects of E2 treatment were compared with ethanol 
solvent control (Ctrl) treatment. B. Immunoblotting of MCF-7 cells treated with E2 as above. C. MCF-7 cells were pre-treated with 1 μM 
actinomycin D for 1 hour before adding 1 nM E2. HIF-2α mRNA was quantified by RT-qPCR and normalized to the initial levels (100%). 
No significant difference between the linear regression slopes of the DMSO solvent control (Ctrl) and E2 treatment was found (n = 3).
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Figure 6: Role of histone deacetylation in E2-dependent HIF-2α regulation. MCF-7 cells were treated with 10 nM E2 with 
or without 250 nM trichostatin A (TSA), an inhibitor of HDAC. mRNA (A) and protein (B) levels were determined by RT-qPCR and 
immunoblotting, respectively. C. Dual luciferase reporter gene assays were performed with MDA-MB-231 cells transiently co-transfected 
with a constitutively expressed Renilla luciferase plasmid, an EPAS1-derived ERE1 to 4 driven firefly reporter gene plasmid, and an ERα 
overexpression vector. D. Luciferase reporter gene assays were performed with MCF-7 cells transiently co-transfected with a constitutively 
expressed Renilla luciferase plasmid, an EPAS1-derived ERE3 or ERE4 driven firefly luciferase reporter gene plasmids, and expression 
vectors for ERα, GATA-2 or GATA-3. Shown are mean values ± SEM of three independent experiments. For statistical mRNA evaluation 
(A), the effects of E2 alone were compared with DMSO solvent control (Ctrl) or with TSA or with TSA+E2 treatment. For statistical 
protein evaluation (B, lower panel), the values were normalized to the DMSO solvent control (Ctrl) and the effects of E2 alone were 
compared with TSA or with TSA+E2 treatment. For dual-luciferase reporter gene assays (C and D), three independent experiments were 
performed in triplicates. The relative luciferase activity was obtained by dividing the firefly luciferase values by the corresponding Renilla 
luciferase values. For statistical evaluation, the effects of E2 treatment were compared with ethanol solvent control (Ctrl) treatment. 
*P<0.05; **P<0.01; ***P<0.001.
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(Figure 6B) downregulation by E2, suggesting that 
HDACs are involved in HIF-2α regulation by E2.
According to published chromatin 
immunoprecipitation-sequencing (ChIP-seq) data 
[17], ERα binds to four distinct regions within the first 
intron of the gene encoding HIF-2α (EPAS1) upon E2 
treatment (Supplementary Figure 3A). In silico analysis 
of the ChIP-seq information deposited in the UCSC-
integrated ENCODE database revealed that these regions 
contained conserved estrogen response element (ERE) 
binding motifs. As shown in Supplementary Figure 3B, 
all four regions displayed robust DNaseI hypersensitivity 
(reflecting open chromatin) and the methylated and 
acetylated histone marks H3K4Me1 and H3K27Ac, 
respectively (reflecting active enhancers) but not 
H3K4Me3 (reflecting active promoters). HDAC binding 
may be transient and was only found in ERE2 (HDAC2). 
Specifically, in K562 erythroleukemia cells HDAC1/2 
binding to ERE3 and HDAC1 binding to ERE4 but no 
HDAC binding to ERE1 and ERE2 could be detected 
(Supplementary Figure 3B). In T-47D breast cancer cells, 
ERE4 also displayed binding of ERα (data not shown). 
Interestingly, transcription factor (TF) ChIP-seq data 
further revealed the binding of GATA-2 and GATA-3, 
established transcriptional repressors [42-45], at ERE3 and 
ERE4 (Supplementary Figure 3B). Moreover, ERα also 
binds to an ERE within the HIF1A gene, overlapping with 
GATA-3 binding (data not shown).
To independently analyze the binding of ERα to the 
EREs 1 to 4 of the EPAS1 gene, we evaluated the potential 
of the ERE DNA fragments (as indicated by red bars in 
Supplementary Figure 3A) to regulate firefly luciferase 
reporter gene expression driven by the heterologous SV40 
promoter. The reporter gene constructs were transiently 
transfected into MDA-MB-231 cells together with an ERα 
overexpression vector. Transfected cells were treated with 
E2 for 24 hours under normoxic or hypoxic conditions 
and the luciferase activities were determined. ERE1 and 
ERE2 had no effects but ERE3 and ERE4 significantly 
enhanced E2-induced reporter gene activity in normoxia 
and ERE4 in hypoxia (Figure 6C). Whereas this result 
using “non-chromatinised” bacterial DNA is opposing to 
the endogenous HIF-2α mRNA regulation by E2, it still 
provides further evidence for functional interaction between 
activated ERα and distinct EREs of the EPAS1 gene.
Plasmids containing ERE3 and ERE4 were then 
transfected into another breast cancer cell line (MCF-
7), with or without ERα, GATA-2 or GATA-3. While 
co-transfection of the reporter genes together with ERα 
or GATA overexpression vector alone did not result 
in significant induction of luciferase activities upon 
E2 treatment, co-overexpression of ERα together with 
GATA-2 or GATA-3 resulted in significant E2-dependent 
activation of luciferase activity in normoxia and hypoxia 
(Figure 6D). Taken together, these results indicate that 
E2-activated ERα locates to at least one ERE within 
the EPAS1 gene and recruits several transcriptional co-
factors, including GATA factors and HDACs, leading to 
transcriptional repression of the EPAS1 gene.
DISCUSSION
Cross-talk between estrogen signaling and hypoxia-
dependent signaling pathways has previously been 
reported, focussing on the interactions between estrogen 
signaling and HIF-1α regulation [27, 32, 37, 46, 47]. In the 
present study, we report for the first time the association 
between estrogen signaling and HIF-2α regulation. 
Estrogen signaling is an essential component of breast 
cancer progression as indicated by the prevalence of ERα 
overexpression in breast cancer patients [48]. Hypoxia 
represents another major factor in breast cancer progression, 
and the interaction between these two signaling pathways 
hence is of major clinical importance [4].
In this study, we observed an ERα-dependent 
downregulation of HIF-2α mRNA and protein levels by 
E2. Cell lines with different ERα status, pharmacological 
and RNA interference experiments confirmed the 
requirement of ERα for the E2 effects on HIF-2α. Higher 
constitutive expression of HIF-2α both on the mRNA and 
protein levels in ERα depleted MCF-7 was phenocopied 
in microarray data of breast cancer patients with different 
ERα levels. This observation suggests a constitutive ERα-
dependent suppression of HIF-2α expression, which is 
strengthened by hormonal ERα activation. Of note, the 
E2-induced HIF-2α repression was almost completely 
abrogated in hormone receptor and HER2 triple-positive 
cells. While it is currently unclear how HER2 interferes 
with HIF-2α regulation, HER2 signalling is known to 
induce HIF-1α by PI3K/Akt/mTOR signalling [49-
51], and a similar mechanism might also overcome E2-
mediated HIF-2α repression.
The ERα utilizes multiple mechanisms to either 
induce or suppress transcription of its target genes, 
which include direct binding of ligand-activated receptor 
to the DNA at the EREs, followed by recruitment of 
transcriptional co-regulators [52, 53]. Also an indirect 
modulation via sequestration of general transcriptional 
components has been suggested [54]. ERα activation is 
usually assumed to be associated with increased gene 
expression, however in fact almost 70% of the genes 
regulated by E2 are down-regulated in MCF-7 [55]. Our 
observation of HIF-2α down-regulation by E2 is thus 
consistent with the majority of genes being downregulated 
upon E2 treatment of MCF-7 cells.
Currently, we have no definitive explanation for 
the mechanism by which ERα inhibits HIF-2α. The state 
of histone acetylation is a predictor of gene activity, 
and HDACs are known to repress gene expression by 
modulating the conformational state of the chromatin. 
Furthermore, HDACs have been reported to be involved 
in tumorigenesis [56, 57]. Estrogen-mediated repression 
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of the cell cycle inhibitor Reprimo (RPRM) required 
the interactions between ERα, HDAC7 and FoxA1 [58]. 
In addition, expression of the gene encoding human 
uridine diphosphate glucuronosyltransferase (UGT1A) 
was inhibited in the presence of ERα. ChIP assays further 
demonstrated the recruitment of ERα, HDAC1 and HDAC2 
to the xenobiotic response elements of UGT1A promoters 
during gene repression [59]. Moreover, tamoxifen-bound 
ERα has been reported to recruit HDAC to silence gene 
transcription of ERα targets [60]. Interestingly, tamoxifen 
treatment of MCF-7 cells has recently been shown to 
significantly increase HDAC1 binding on the ERE of HIF-
1α [32]. In our study, treatment of MCF-7 cells with E2 
and TSA abolished ERα-dependent HIF-2α regulation. 
We identified several EREs within the regulatory region 
of the EPAS1 gene, and ERE4 interacts with ERα in both 
MCF-7 and T-47D cells. ERE4 can also interact with 
GATA-2 and GATA-3, consistent with recent studies 
revealing substantial enrichment of GATA3 binding to 
ERα occupied DNA regions [61, 62]. Furthermore, besides 
inducing gene expression, GATAs have been reported to 
also exert repressive functions [42-45]. Luciferase reporter 
gene assays demonstrated a functional interaction between 
GATA-2/3 and the EPAS1 ERE4, suggesting a role of 
ERE4 in ERα-dependent HIF-2α regulation.
In conclusion, hormone activation may lead to 
enhanced ERα dimerization, binding to EPAS1 ERE4, 
recruitment of transcriptional co-factors, including GATAs 
and HDACs, and repression of gene expression. The 
lack of ERα in triple-negative breast cancer cells allows 
for constitutively higher HIF-2α and prevents estrogen-
mediated HIF-2α downregulation seen in ERα positive 
breast cancer cells. This model is consistent with the inverse 
correlation between ERα and HIF-2α mRNA levels, which 
we observed in several breast cancer gene array studies.
Intriguingly, the current study using 690 breast 
cancer tissue samples could only partially confirm the 
previously reported positive correlation between HIF-
2α protein levels and overall patient survival [11]. In 
the previous study, we analyzed a smaller cohort of 282 
invasive breast cancer cases containing mainly ERα 
positive and HER2 negative luminal A/B samples, with 
only 13 cases being HER2 positive [11]. In the current 
study, we used a different and much larger cohort, 
including 90 HER2 positive cases and 82 triple-negative 
samples. Moreover, different antibodies, pretreatment 
protocols and the nuclear vs. cytoplasmic signal scoring 
scheme applied in the current study may have contributed 
to the incomplete overlap between the results of the two 
studies. The correlation between high nuclear HIF-2α 
and shortened overall survival in the HER2 and hormone 
receptor positive patient sub-cohort may be due to the 
attenuated downregulation of HIF-2α upon E2 treatment 
in HER2 positive breast cancer cells.
MATERIALS AND METHODS
Reagents
E2 (17β-estradiol), PPT (propyl pyrazole triol), 
tamoxifen, fulvestrant and actinomycin D were purchased 
from Sigma-Aldrich (St Louis, MO, USA). G-1 was 
purchased from Tocris Biosciene (Bristol, UK). Reagents 
were dissolved in ethanol or dimethyl sulfoxide (DMSO). 
Antibodies against the following proteins were used: 
HIF-1α (BD Transduction Laboratories, Allschwil, 
Switzerland), HIF-2α (immunoblotting: Abnova 
Corporation, Taiwan; immunohistochemistry: Abcam, 
Cambridge, UK), ERα (Santa Cruz Biotechnology, Dallas, 
TX, USA), and β-actin (Sigma-Aldrich).
Cell culture and treatments
The human breast cancer cell lines MCF-7, T-47D, 
MDA-MB-231, MDA-MB-468, ZR-75-1 and BT-474 were 
cultured in high-glucose Dulbecco’s Modified Eagle’s 
Medium (Sigma-Aldrich). Before experiments, the cells 
were maintained in phenol red-free DMEM supplemented 
with 10% charcoal-treated FCS (Gibco, Thermo Fischer 
Scientific, Waltham, MA, USA) for 1 to 2 days. Cells were 
treated with E2 or vehicle control (0.1% ethanol or 0.1% 
DMSO) alone or in combination with other ligands for 24 
hours under normoxic and hypoxic conditions. Hypoxic 
experiments were performed at 0.2% oxygen and 5% 
CO2 in a gas-controlled glove box (Invivo2 400, Baker 
Ruskinn, Bridgend, UK) as described previously [63].
mRNA and protein detection and quantification
Total cellular RNA was extracted as previously 
described [11]. Total RNA (2 μg) was reverse transcribed 
(RT) using AffinityScript reverse transcriptase (Agilent, 
Santa Clara, CA, USA) and complementary DNA (cDNA) 
levels were estimated by quantitative polymerase chain 
reaction (qPCR) using the primers listed in Supplementary 
Table 1A and a SYBR® Green qPCR reagent kit (Sigma-
Aldrich) in a MX3000P light cycler (Agilent). Transcript 
levels were calculated by comparison with a calibrated 
standard and expressed as ratios relative to ribosomal 
protein L28 mRNA levels. Immunoblotting, signal 
imaging and quantification were performed as previously 
reported [64]. Values were normalized to a β-actin loading 
control. Breast cancer tissue microarray analysis was 
performed as previously described [38].
Plasmid construction and reporter gene assays
DNA fragments containing the EPAS1-derived 
EREs were generated by PCR using the primers listed 
in Supplementary Table 1B, and cloned into the pGL3-
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promoter luciferase reporter vector (Promega Corporation, 
Madison, WI, USA). A cDNA encoding human ERα 
cloned into the pCMV5 mammalian expression vector 
was kindly provided by A. Odermatt (Basel, Switzerland). 
Human GATA-2, GATA-3, and GATA-4 cloned into 
pcDNA3.1 were kindly provided by C. Dame (Berlin, 
Germany). Dual luciferase reporter gene assays were 
performed as described previously [64].
In silico expression data
The R2 database (http://hgserver1.amc.nl/cgi-
bin/r2/main.cgi) was searched using the across datasets 
and 2D gene overview options for correlations between 
EPAS1 and ESR1 in Affymetrix HG-U133plus2.0 
based expression profiles normalized using MAS5. 
The following GEO IDs were employed: GSE29431 
(r-value=-0.590, p-value=1.9e-07, 66 samples), 
GSE28844 (r-value=-0.349 p-value=5.8e-03, 61 samples), 
GSE12093 (r-value=-0.438 p-value=9.9e-08, 136 
samples) and GSE5462 (r-value=-0.313 p-value=6.2e-04, 
116 samples).
Statistical analysis
If not indicated otherwise, unpaired Student’s t-tests 
were applied. Differences between two values at the 
P<0.05 level were considered to be statistically significant.
ACKNOWLEDGMENTS
We thank P. Spielmann for excellent 
technical assistance; A. Odermatt and C. Dame for 
providing plasmids; and A. Fitsche for the TMA 
immunohistochemistry.
FUNDING
This project was supported by the Swiss National 
Science Foundation grant 31003A_146203 and the KFSP 
Tumor Oxygenation of the University of Zurich. K.G. 
was supported by a grant from the Vontobel-Stiftung 
(Switzerland).
CONFLICTS OF INTEREST
The authors declare no conflicts of interest in this 
work.
REFERENCES
1. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, 
Ratcliffe PJ, Harris AL. The expression and distribution of 
the hypoxia-inducible factors HIF-1α and HIF-2α in normal 
human tissues, cancers, and tumor-associated macrophages. 
Am J Pathol. 2000; 157: 411-421.
2. Gatenby RA, Gillies RJ. Why do cancers have high aerobic 
glycolysis? Nat Rev Cancer. 2004; 4: 891-899.
3. Bertout JA, Patel SA, Simon MC. The impact of O2 
availability on human cancer. Nat Rev Cancer. 2008; 8: 
967-975.
4. Semenza GL. The hypoxic tumor microenvironment: 
A driving force for breast cancer progression. Biochim 
Biophys Acta. 2016; 1863: 382-391.
5. Wenger RH, Hoogewijs D. Regulated oxygen sensing by 
protein hydroxylation in renal erythropoietin-producing 
cells. Am J Physiol Renal Physiol. 2010; 298: F1287-1296.
6. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera 
R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, 
Borg A, Gradin K, Poellinger L, Pahlman S. Recruitment of 
HIF-1α and HIF-2α to common target genes is differentially 
regulated in neuroblastoma: HIF-2α promotes an aggressive 
phenotype. Cancer Cell. 2006; 10: 413-423.
7. Stiehl DP, Wirthner R, Köditz J, Spielmann P, Camenisch 
G, Wenger RH. Increased prolyl 4-hydroxylase domain 
proteins compensate for decreased oxygen levels. Evidence 
for an autoregulatory oxygen-sensing system. J Biol Chem. 
2006; 281: 23482-23491.
8. Semenza GL. Defining the role of hypoxia-inducible factor 
1 in cancer biology and therapeutics. Oncogene. 2010; 29: 
625-634.
9. Pahlman S, Lund LR, Jogi A. Differential HIF-1α and 
HIF-2α expression in mammary epithelial cells during fat 
pad invasion, lactation, and involution. PLoS One. 2015; 
10: e0125771.
10. Aprelikova O, Wood M, Tackett S, Chandramouli GV, 
Barrett JC. Role of ETS transcription factors in the hypoxia-
inducible factor-2 target gene selection. Cancer Res. 2006; 
66: 5641-5647.
11. Stiehl DP, Bordoli MR, Abreu-Rodríguez I, Wollenick K, 
Schraml P, Gradin K, Poellinger L, Kristiansen G, Wenger 
RH. Non-canonical HIF-2α function drives autonomous 
breast cancer cell growth via an AREG-EGFR/ErbB4 
autocrine loop. Oncogene. 2012; 31: 2283-2297.
12. Findlay JK, Liew SH, Simpson ER, Korach KS. Estrogen 
signaling in the regulation of female reproductive functions. 
Handbook of experimental pharmacology. 2010: 29-35.
13. Gillies GE, McArthur S. Estrogen actions in the brain 
and the basis for differential action in men and women: a 
case for sex-specific medicines. Pharmacol Rev. 2010; 62: 
155-198.
14. Murphy E. Estrogen signaling and cardiovascular disease. 
Circ Res. 2011; 109: 687-696.
15. Stingl J. Estrogen and progesterone in normal mammary 
gland development and in cancer. Hormones & cancer. 
2011; 2: 85-90.
16. Manolagas SC, O'Brien CA, Almeida M. The role of 
estrogen and androgen receptors in bone health and disease. 
Nat Rev Endocrinol. 2013; 9: 699-712.
Oncotarget12www.impactjournals.com/oncotarget
17. Welboren WJ, van Driel MA, Janssen-Megens EM, van 
Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG. 
ChIP-Seq of ERα and RNA polymerase II defines genes 
differentially responding to ligands. EMBO J. 2009; 28: 
1418-1428.
18. Driscoll MD, Sathya G, Muyan M, Klinge CM, Hilf R, 
Bambara RA. Sequence requirements for estrogen receptor 
binding to estrogen response elements. J Biol Chem. 1998; 
273: 29321-29330.
19. Yager JD, Davidson NE. Estrogen carcinogenesis in breast 
cancer. N Engl J Med. 2006; 354: 270-282.
20. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of 
cancer prevalence for 27 sites in the adult population in 
2008. Int J Cancer. 2013; 132: 1133-1145.
21. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence 
and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 
E359-386.
22. Ali S, Coombes RC. Estrogen receptor α in human breast 
cancer: occurrence and significance. J Mammary Gland 
Biol Neoplasia. 2000; 5: 271-281.
23. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, 
Rosano C, Maggiolini M. MIBE acts as antagonist ligand of 
both estrogen receptor α and GPER in breast cancer cells. 
Breast Cancer Res. 2012; 14: R12.
24. Coradini D, Pellizzaro C, Speranza A, Daidone MG. 
Hypoxia and estrogen receptor profile influence the 
responsiveness of human breast cancer cells to estradiol and 
antiestrogens. Cell Mol Life Sci. 2004; 61: 76-82.
25. Mukundan H, Kanagy NL, Resta TC. 17-β estradiol 
attenuates hypoxic induction of HIF-1α and erythropoietin 
in Hep3B cells. J Cardiovasc Pharmacol. 2004; 44: 93-100.
26. Yi JM, Kwon HY, Cho JY, Lee YJ. Estrogen and hypoxia 
regulate estrogen receptor α in a synergistic manner. 
Biochem Biophys Res Commun. 2009; 378: 842-846.
27. Lim W, Park Y, Cho J, Park C, Park J, Park YK, Park H, 
Lee Y. Estrogen receptor β inhibits transcriptional activity 
of hypoxia inducible factor-1 through the downregulation 
of arylhydrocarbon receptor nuclear translocator. Breast 
Cancer Res. 2011; 13: R32.
28. Sudhagar S, Sathya S, Lakshmi BS. Rapid non-genomic 
signalling by 17β-oestradiol through c-Src involves mTOR-
dependent expression of HIF-1α in breast cancer cells. Br J 
Cancer. 2011; 105: 953-960.
29. Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson 
PH. Intermittent hypoxia induces proteasome-dependent 
down-regulation of estrogen receptor α in human breast 
carcinoma. Clin Cancer Res. 2004; 10: 8720-8727.
30. Seifeddine R, Dreiem A, Tomkiewicz C, Fulchignoni-
Lataud MC, Brito I, Danan JL, Favaudon V, Barouki R, 
Massaad-Massade L. Hypoxia and estrogen co-operate to 
regulate gene expression in T-47D human breast cancer 
cells. J Steroid Biochem Mol Biol. 2007; 104: 169-179.
31. George AL, Rajoria S, Suriano R, Mittleman A, Tiwari RK. 
Hypoxia and estrogen are functionally equivalent in breast 
cancer-endothelial cell interdependence. Mol Cancer. 2012; 
11: 80.
32. Yang J, AlTahan A, Jones DT, Buffa FM, Bridges E, 
Interiano RB, Qu C, Vogt N, Li JL, Baban D, Ragoussis 
J, Nicholson R, Davidoff AM et al. Estrogen receptor-α 
directly regulates the hypoxia-inducible factor 1 pathway 
associated with antiestrogen response in breast cancer. Proc 
Natl Acad Sci USA. 2015; 112: 15172-15177.
33. De Francesco EM, Pellegrino M, Santolla MF, Lappano 
R, Ricchio E, Abonante S, Maggiolini M. GPER mediates 
activation of HIF1α/VEGF signaling by estrogens. Cancer 
Res. 2014; 74: 4053-4064.
34. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, 
Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green 
AR, Ali S, Chin SF, Palmieri C et al. Differential oestrogen 
receptor binding is associated with clinical outcome in 
breast cancer. Nature. 2012; 481: 389-393.
35. Fuady JH, Bordoli MR, Abreu-Rodríguez I, Kristiansen G, 
Hoogewijs D, Stiehl DP, Wenger RH. Hypoxia-inducible 
factor-mediated induction of WISP-2 contributes to 
attenuated progression of breast cancer. Hypoxia. 2014; 2: 
23-33.
36. Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo 
MS, Banerjee SK. WISP-2 gene in human breast cancer: 
estrogen and progesterone inducible expression and 
regulation of tumor cell proliferation. Neoplasia. 2003; 5: 
63-73.
37. Chen M, Xiao D, Hu XQ, Dasgupta C, Yang S, Zhang L. 
Hypoxia represses ER-α expression and inhibits estrogen-
induced regulation of Ca2+-activated K+ channel activity and 
myogenic tone in ovine uterine arteries: causal role of DNA 
methylation. Hypertension. 2015; 66: 44-51.
38. Pomp V, Leo C, Mauracher A, Korol D, Guo W, Varga Z. 
Differential expression of epithelial-mesenchymal transition 
and stem cell markers in intrinsic subtypes of breast cancer. 
Breast Cancer Res Treat. 2015.
39. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley 
P, Xing L, Hung MC, Bonfiglio T, Hicks DG, Tang P. The 
expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 
and AR by immunohistochemical analysis in breast cancer 
cell lines. Breast cancer (Auckl). 2010; 4: 35-41.
40. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor 
(HIF)-1α versus HIF-2α in the regulation of HIF target 
genes in response to hypoxia, insulin-like growth factor-I, 
or loss of von Hippel-Lindau function: implications 
for targeting the HIF pathway. Cancer Res. 2006; 66: 
6264-6270.
41. Wang V, Davis DA, Haque M, Huang LE, Yarchoan R. 
Differential gene up-regulation by hypoxia-inducible 
factor-1α and hypoxia-inducible factor-2α in HEK293T 
cells. Cancer Res. 2005; 65: 3299-3306.
Oncotarget13www.impactjournals.com/oncotarget
42. Imagawa S, Yamamoto M, Miura Y. GATA transcription 
factors negatively regulate erythropoietin gene expression. 
Acta Haematol. 1996; 95: 248-256.
43. Imagawa S, Yamamoto M, Miura Y. Negative regulation 
of the erythropoietin gene expression by the GATA 
transcription factors. Blood. 1997; 89: 1430-1439.
44. Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ, Bresnick EH. 
GATA-1-dependent transcriptional repression of GATA-2 
via disruption of positive autoregulation and domain-wide 
chromatin remodeling. Proc Natl Acad Sci USA. 2003; 100: 
8811-8816.
45. Xiong Y, Castro E, Yagi R, Zhu J, Lesourne R, Love PE, 
Feigenbaum L, Bosselut R. Thpok-independent repression 
of Runx3 by Gata3 during CD4+ T-cell differentiation in 
the thymus. Eur J Immunol. 2013; 43: 918-928.
46. Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, 
Kanagawa H, Katsuyama E, Fujie A, Hao W, Miyamoto 
K, Tando T, Morioka H, Matsumoto M et al. HIF1α is 
required for osteoclast activation by estrogen deficiency 
in postmenopausal osteoporosis. Proc Natl Acad Sci USA. 
2013; 110: 16568-16573.
47. Xu D, Niu W, Luo Y, Zhang B, Liu M, Dong H, Liu Y, 
Li Z. Endogenous estrogen attenuates hypoxia-induced 
pulmonary hypertension by inhibiting pulmonary arterial 
vasoconstriction and pulmonary arterial smooth muscle 
cells proliferation. Int J Med Sci. 2013; 10: 771-781.
48. Ferguson AT, Davidson NE. Regulation of estrogen 
receptor α function in breast cancer. Crit Rev Oncog. 1997; 
8: 29-46.
49. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza 
GL. HER2 (neu) signaling increases the rate of hypoxia-
inducible factor 1α (HIF-1α) synthesis: novel mechanism 
for HIF-1-mediated vascular endothelial growth factor 
expression. Mol Cell Biol. 2001; 21: 3995-4004.
50. Li YM, Zhou BP, Deng J, Pan Y, Hay N, Hung MC. A 
hypoxia-independent hypoxia-inducible factor-1 activation 
pathway induced by phosphatidylinositol-3 kinase/Akt 
in HER2 overexpressing cells. Cancer Res. 2005; 65: 
3257-3263.
51. Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis 
G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. 
Nonhypoxic regulation and role of hypoxia-inducible factor 
1 in aromatase inhibitor resistant breast cancer. Breast 
Cancer Res. 2014; 16: R15.
52. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, 
Uht RM, Webb P. Estrogen receptor pathways to AP-1. J 
Steroid Biochem Mol Biol. 2000; 74: 311-317.
53. Safe S. Transcriptional activation of genes by 17 β-estradiol 
through estrogen receptor-Sp1 interactions. Vitam Horm. 
2001; 62: 231-252.
54. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, 
Karathanasis SK. The role of CBP in estrogen receptor 
cross-talk with nuclear factor-κB in HepG2 cells. 
Endocrinology. 2000; 141: 3403-3411.
55. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, 
Katzenellenbogen BS. Profiling of estrogen up- and down-
regulated gene expression in human breast cancer cells: 
insights into gene networks and pathways underlying 
estrogenic control of proliferation and cell phenotype. 
Endocrinology. 2003; 144: 4562-4574.
56. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi 
T, Takahashi T. Reduced expression of class II histone 
deacetylase genes is associated with poor prognosis in lung 
cancer patients. Int J Cancer. 2004; 112: 26-32.
57. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl 
AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert 
C. Class I histone deacetylase expression has independent 
prognostic impact in human colorectal cancer: specific role 
of class I histone deacetylases in vitro and in vivo. Clin 
Cancer Res. 2008; 14: 1669-1677.
58. Malik S, Jiang S, Garee JP, Verdin E, Lee AV, O'Malley 
BW, Zhang M, Belaguli NS, Oesterreich S. Histone 
deacetylase 7 and FoxA1 in estrogen-mediated repression 
of RPRM. Mol Cell Biol. 2010; 30: 399-412.
59. Kalthoff S, Winkler A, Freiberg N, Manns MP, Strassburg 
CP. Gender matters: estrogen receptor α (ERα) and histone 
deacetylase (HDAC) 1 and 2 control the gender-specific 
transcriptional regulation of human uridine diphosphate 
glucuronosyltransferases genes (UGT1A). J Hepatol. 2013; 
59: 797-804.
60. Huang HJ, Norris JD, McDonnell DP. Identification of a 
negative regulatory surface within estrogen receptor α 
provides evidence in support of a role for corepressors in 
regulating cellular responses to agonists and antagonists. 
Mol Endocrinol. 2002; 16: 1778-1792.
61. Osmanbeyoglu HU, Lu KN, Oesterreich S, Day RS, 
Benos PV, Coronnello C, Lu X. Estrogen represses gene 
expression through reconfiguring chromatin structures. 
Nucl Acids Res. 2013; 41: 8061-8071.
62. Theodorou V, Stark R, Menon S, Carroll JS. GATA3 acts 
upstream of FOXA1 in mediating ESR1 binding by shaping 
enhancer accessibility. Genome Res. 2013; 23: 12-22.
63. Storti F, Santambrogio S, Crowther L, Otto T, Abreu-
Rodríguez I, Kaufmann M, Hu CJ, Dame C, Fandrey 
J, Wenger RH, Hoogewijs D. A novel distal upstream 
hypoxia response element regulating oxygen-dependent 
erythropoietin gene expression. Haematologica. 2014; 99: 
e45-e48.
64. Schörg A, Santambrogio S, Platt JL, Schödel J, 
Lindenmeyer MT, Cohen CD, Schrödter K, Mole DR, 
Wenger RH, Hoogewijs D. Destruction of a distal hypoxia 
response element abolishes trans-activation of the PAG1 
gene mediated by HIF-independent chromatin looping. 
Nucl Acids Res. 2015; 43: 5810-5823.
